Mycenax Biotech (4726) - Net Assets
Based on the latest financial reports, Mycenax Biotech (4726) has net assets worth NT$1.64 Billion TWD (≈ $51.75 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.33 Billion ≈ $104.88 Million USD) and total liabilities (NT$1.69 Billion ≈ $53.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Mycenax Biotech's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.64 Billion |
| % of Total Assets | 49.34% |
| Annual Growth Rate | 8.49% |
| 5-Year Change | 67.0% |
| 10-Year Change | N/A |
| Growth Volatility | 33.3 |
Mycenax Biotech - Net Assets Trend (2017–2024)
This chart illustrates how Mycenax Biotech's net assets have evolved over time, based on quarterly financial data. Also explore Mycenax Biotech assets under control for the complete picture of this company's asset base.
Annual Net Assets for Mycenax Biotech (2017–2024)
The table below shows the annual net assets of Mycenax Biotech from 2017 to 2024. For live valuation and market cap data, see 4726 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.02 Billion ≈ $63.75 Million |
-17.31% |
| 2023-12-31 | NT$2.45 Billion ≈ $77.10 Million |
-21.20% |
| 2022-12-31 | NT$3.11 Billion ≈ $97.84 Million |
+62.88% |
| 2021-12-31 | NT$1.91 Billion ≈ $60.07 Million |
+57.36% |
| 2020-12-31 | NT$1.21 Billion ≈ $38.17 Million |
+9.96% |
| 2019-12-31 | NT$1.10 Billion ≈ $34.72 Million |
+21.49% |
| 2018-12-31 | NT$907.01 Million ≈ $28.58 Million |
-20.71% |
| 2017-12-31 | NT$1.14 Billion ≈ $36.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mycenax Biotech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27743800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$2.49 Billion | 123.07% |
| Total Equity | NT$2.02 Billion | 100.00% |
Mycenax Biotech Competitors by Market Cap
The table below lists competitors of Mycenax Biotech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lippo Cikarang Tbk
JK:LPCK
|
$191.05 Million |
|
Elme Communities
NYSE:ELME
|
$191.13 Million |
|
Sinmag Equipment
TWO:1580
|
$191.20 Million |
|
Urbana Corporation
TO:URB-A
|
$191.22 Million |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
$191.02 Million |
|
Gem Terminal Industry Co Ltd
TW:2460
|
$190.84 Million |
|
AMA Group Ltd
AU:AMA
|
$190.78 Million |
|
Hi-Clearance
TWO:1788
|
$190.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mycenax Biotech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,447,192,000 to 2,023,479,000, a change of -423,713,000 (-17.3%).
- Net loss of 467,125,000 reduced equity.
- New share issuances of 35,968,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-467.12 Million | -23.09% |
| Share Issuances | NT$35.97 Million | +1.78% |
| Other Changes | NT$7.44 Million | +0.37% |
| Total Change | NT$- | -17.31% |
Book Value vs Market Value Analysis
This analysis compares Mycenax Biotech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.99x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.81x to 2.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$10.41 | NT$29.25 | x |
| 2018-12-31 | NT$8.25 | NT$29.25 | x |
| 2019-12-31 | NT$10.02 | NT$29.25 | x |
| 2020-12-31 | NT$9.45 | NT$29.25 | x |
| 2021-12-31 | NT$12.43 | NT$29.25 | x |
| 2022-12-31 | NT$15.13 | NT$29.25 | x |
| 2023-12-31 | NT$11.90 | NT$29.25 | x |
| 2024-12-31 | NT$9.77 | NT$29.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mycenax Biotech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.30%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.66x
- Recent ROE (-23.09%) is below the historical average (-16.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -16.47% | -59.12% | 0.24x | 1.15x | NT$-302.76 Million |
| 2018 | -30.26% | -129.80% | 0.19x | 1.23x | NT$-365.13 Million |
| 2019 | -19.80% | -55.82% | 0.28x | 1.28x | NT$-328.37 Million |
| 2020 | 2.55% | 4.65% | 0.38x | 1.45x | NT$-90.22 Million |
| 2021 | -4.71% | -11.61% | 0.25x | 1.65x | NT$-280.52 Million |
| 2022 | -14.61% | -61.95% | 0.16x | 1.43x | NT$-764.19 Million |
| 2023 | -27.90% | -104.63% | 0.17x | 1.54x | NT$-927.57 Million |
| 2024 | -23.09% | -68.30% | 0.20x | 1.66x | NT$-669.47 Million |
Industry Comparison
This section compares Mycenax Biotech's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,782,670,400
- Average return on equity (ROE) among peers: 2.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mycenax Biotech (4726) | NT$1.64 Billion | -16.47% | 1.03x | $191.04 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more